---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-074706"
form_type: "8-K"
ticker: "NTLA"
cik: "0001652130"
company_name: "Intellia Therapeutics, Inc."
filed_at: "2024-03-22T23:59:59+00:00"
generated_at: "2026-06-04T09:04:40.453911+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Intellia terminates Factor IX co-development agreement with Regeneron; retains milestone/royalty rights under LCA

## Summary
- On March 19, 2024, Intellia gave notice to Regeneron to exit the Factor IX Co-Development and Co-Funding Agreement, effective after 180 days.
- Intellia will no longer share 35% of development costs or receive 35% of profits for Factor IX gene editing products upon termination.
- Under the existing License and Collaboration Agreement (LCA), Intellia remains eligible for up to $320M in milestones and high-single to low-teen royalties.
- Other collaboration programs with Regeneron under the LCA are unaffected by this termination.

## SEC filing metadata
- accession: 0001193125-24-074706
- form_type: 8-K
- ticker: NTLA
- cik: 0001652130
- company_name: Intellia Therapeutics, Inc.
- filed_at: 2024-03-22T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1652130/000119312524074706/0001193125-24-074706-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1652130/000119312524074706/d17601d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-074706
- JSON: https://secwatch.observer/filing/0001193125-24-074706.json
- Plain text: https://secwatch.observer/filing/0001193125-24-074706.txt

## Key facts
- Material Agreements
  Intellia Therapeutics, Inc. terminated Factor IX Co-Development and Co-Funding Agreement with Regeneron Pharmaceuticals, Inc. (effective 2024-03-19).
  - Action: termination
  - Agreement: collaboration
  - Counterparty: Regeneron Pharmaceuticals, Inc.
  - Effective: 2024-03-19
  source text: On March 19, 2024, Intellia Therapeutics, Inc. (the “Company” or “Intellia”) notified Regeneron Pharmaceuticals, Inc. (“Regeneron”) that the Company is opting out of its Factor IX Co-Development and Co-Funding Agreement (the “Co-Co Agreement”), which the Company and Regeneron entered into in May 2020.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1652130/000119312524074706/0001193125-24-074706-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.